<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00431145</url>
  </required_header>
  <id_info>
    <org_study_id>20091977</org_study_id>
    <nct_id>NCT00431145</nct_id>
  </id_info>
  <brief_title>Niacin As Secondary Prevention Of Coronary Artery Disease (NASPOCAD)</brief_title>
  <official_title>Influence of Combined Therapy of Niacin and Statins on Stem Cell Mobilization and Inflammatory Parameters in Patients Suffering From Coronary Artery Disease â€“ Randomized Clinical Study -</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <brief_summary>
    <textblock>
      Aim of the study is to show additional effects of the combined therapy of niacin and statins
      analyzing number and function of EPCs and other stem cell populations and adiponectin as well
      as hsCRP levels in patients with CAD.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2006</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>numbers of EPCs and inflammatory markers</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>adiponectin</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>hsCRP</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>each after 8 weeks</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>numbers of EPCs,</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory markers</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adiponectin</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hsCRP</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>each after 4 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number and type of progenitor cells</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dendritic cells</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cytokines</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lipoproteins in peripheral blood</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vascular function</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>each after 4 and 8 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>carotid artery distensibility</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>carotid artery plaque composition</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>each after 8 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>optionally 1 year follow-up</measure>
  </secondary_outcome>
  <enrollment>80</enrollment>
  <condition>Coronary Artery Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niacin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niacin+Statin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be at least 18 years old, male or female

          -  Have stable coronary artery disease (i.e. no acute event like myocardial infarction or
             PTCA less then 3 months ago)

          -  LDL &gt; 100 mg/dl

          -  HDL &lt; 50 mg/dl

          -  Triglycerides &lt; 400 mg/dl

          -  No Nicotine abuse for at least 3 months

          -  Statin-therapy for more than 4 weeks

          -  Give a written informed consent

          -  Have the ability to understand the requirements of the study, and agree and be able to
             return for the required assessments.

        Exclusion Criteria:

          -  Women of childbearing potential, pregnancy or being lactating

          -  Current participation in another clinical trial

          -  Have other severe concurrent illness (e.g., active infection, malignancy)

          -  Have a history of alcohol or drug abuse within 3 months of admission or factors making
             follow-up difficult or unlikely.

          -  Have significant or unexplained liver dysfunction or chronic increased levels of
             transaminases (ALT, AST)

          -  Suffer from myopathy, active peptic disease or arterial bleeding

          -  Have a known hypersensitivity against niacin or statins

          -  Are actually treated with any of itraconazole, ketoconazole, HIV-Protease-Inhibitors,
             erythromycin, clarithromycin, telithromycin, nefazodone.

          -  Actual therapy with ezetimibe

          -  Diabetes mellitus Type I
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang M Franz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Munich/Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wolfgang M Franz, MD</last_name>
    <phone>++498970956095</phone>
    <email>Wolfgang.Franz@med.uni-muenchen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hans D Theiss, MD</last_name>
    <phone>++498970953074</phone>
    <email>Hans.Theiss@med.uni-muenchen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Munich</name>
      <address>
        <city>Munich</city>
        <zip>80333</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2007</study_first_submitted>
  <study_first_submitted_qc>February 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2007</study_first_posted>
  <last_update_submitted>February 1, 2007</last_update_submitted>
  <last_update_submitted_qc>February 1, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

